Key Takeaways
- Eli Lilly's (LLY) Baricitinib (Olumiant) demonstrated significant scalp hair regrowth in over 50% of adolescents with severe alopecia areata in a Phase 3 trial, with continuous improvements observed through 52 weeks and no new safety concerns.
- Senator Marco Rubio stated that the UNRWA has become a "subsidiary of Hamas" and will not play a role in future humanitarian aid efforts in Gaza, citing concerns over its neutrality.
- Rubio emphasized that Hamas must fully demilitarize and will not be part of Gaza's future governance, with concerns also raised about the Palestinian Authority's current standing.
- The 4mg dose of Baricitinib led to 42.4% of adolescent patients achieving 80% or more scalp hair coverage by Week 36, significantly outperforming placebo.
- Rubio indicated that a "20-point plan" for Gaza's future is in motion, requiring substantial long-term effort, and that the U.S. is not at a stage where a Gaza deal is falling apart.
Eli Lilly and Company (LLY) has announced positive late-breaking results from its Phase 3 BRAVE-AA-PEDS study, showing that its drug Baricitinib (Olumiant) led to significant scalp hair regrowth in adolescents aged 12 to under 18 with severe alopecia areata. Over 50% of adolescents treated with Baricitinib 4mg achieved a successful scalp hair response by Week 52, with successful regrowth also observed with the 2mg dose. The safety profile of Baricitinib remained consistent with previous reports, with no new safety observations.
The study highlighted that 42.4% of patients receiving Baricitinib 4mg achieved 80% or more scalp hair coverage by Week 36, compared to just 4.5% on placebo. Furthermore, 36.5% of patients on the 4mg dose and 21.4% on the 2mg dose achieved 90% or more scalp hair coverage. Significant eyebrow and eyelash regrowth was also observed, with 50.0% of patients on 4mg achieving significant eyebrow regrowth. These 36-week results in adolescents were noted to be comparable to or even faster than outcomes seen in adults after 52 weeks of treatment, suggesting a potentially more rapid response in younger patients. Eli Lilly intends to submit these data to global regulators for a potential label update for Baricitinib.
In geopolitical news, Senator Marco Rubio has made strong statements regarding the future of Gaza and the role of the UN Relief and Works Agency (UNRWA). Rubio asserted that UNRWA has become a "subsidiary of Hamas" and, as such, will not play any role in future humanitarian aid efforts in the territory. This comes amidst ongoing international discussions about aid distribution and governance in Gaza.
Rubio underscored that Gaza must not be used as a launchpad to threaten Israel, and that Hamas must fully demilitarize, with a clear consensus that Hamas will not be part of Gaza's future governing structure. He also expressed concerns about the Palestinian Authority as it currently stands. The Senator mentioned a "20-point plan" for Gaza's future, acknowledging that its implementation will require a significant amount of work over a long period, but indicated that current efforts are "ahead of schedule" and that a Gaza deal is not falling apart.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.